PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy

Cancer immunotherapy has been revolutionised by drugs that enhance the ability of the immune system to detect and fight tumors. Immune checkpoint therapies that target the programmed death-1 receptor (PD-1), or its ligand (PD-L1) have shown unprecedented rates of durable clinical responses in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolfes, Verena, Idel, Christian, Pries, Ralph, Plötze-Martin, Kirstin, Habermann, Jens, Gemoll, Timo, Bohnet, Sabine, Latz, Eicke, Ribbat-Idel, Julika, Franklin, Bernardo S., Wollenberg, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007942/
https://www.ncbi.nlm.nih.gov/pubmed/29937998
http://dx.doi.org/10.18632/oncotarget.25446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007942/
https://www.ncbi.nlm.nih.gov/pubmed/29937998
http://dx.doi.org/10.18632/oncotarget.25446

Ejemplares similares